Abbott Medical Optics, Inc. v Alcon Laboratories, Inc

Link copied
Case Copied 6 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Abbott Medical Optics, Inc. v Alcon Laboratories, Inc. [2012] APO 78

Patent Application:                2004201867

Title:Process for cleaning and disinfecting contact lenses

Patent Applicant:                   Alcon Laboratories, Inc.

Opponent:  Abbott Medical Optics, Inc.

Delegate:  Dr B. Akhurst

Decision Date:  26 July 2012

Hearing Date:  By written submissions dated 12 June 2012 and 29 June 2012

Catchwords:  PATENTS - final determination of an opposition under section 59 -whether amendments overcome the deficiencies in the opposed claims - the claims are directed to the use of a single solution - deficiencies overcome - costs awarded against the opponent 

Representation:  Patent applicant:  Dr Simon Weisman patent attorney of FB Rice & Co., Sydney

Opponent:Dr Trevor Davies and Dr Linda Govenlock, patent attorneys of Allens Arthur Robinson, Sydney

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2004201867

Title:Process for cleaning and disinfecting contact lenses

Patent Applicant:                   Alcon Laboratories, Inc.

Date of Decision:                   26 July 2012

DECISION

The applicant’s amendments of 21 November 2011 overcome all of the deficiencies identified in the earlier decision.  Subject to appeal, I direct that the application proceed to sealing.

REASONS FOR DECISION

BACKGROUND

  1. Grant of a patent for application 2004201867 in the name of Alcon Laboratories, Inc. was opposed by Abbott Medical Optics, Inc.  Following a hearing, on 26 September 2011, I issued a decision upholding the opposition, which was reported as Abbott Medical Optics, Inc. v Alcon Laboratories, Inc. [2011] APO 79. The background to the present matter is presented in this earlier decision.

  2. Alcon filed amendments to the specification under section 104, which were advertised allowed on 31 May 2012.  Both parties filed written submissions for the final determination of the opposition.  Alcon’s were filed on 12 June 2012.  Abbott’s submissions on 29 June 2012 relied in part on comments on the proposed amendments filed on 14 December 2011. 

    The amendments

  3. Compared to the opposed claims, Alcon’s amendments incorporated part of opposed claim 6 into claim 1; added and deleted text in claims 2 and 7, respectively; corrected a typographical error in claim 20; and added two additional claims.  Consequential amendments were made to the dependent claims.

4.   Claim 1 remains the only independent claim.  With the additional text underlined, claim 1 reads as follows:

“A method of cleaning a contact lens with a single solution comprising polycarboxylates(s) or corresponding acid(s) or a combination thereof in an amount effective to clean the lens, wherein said method comprises (i) applying the single solution to the lens for a time and under conditions sufficient to remove debris from the lens, and then (ii) soaking the lens in the single solution for a time and under conditions sufficient to remove protein deposits attached to the lens wherein said time and said conditions do not only disinfect the lens or remove debris.”

  1. The earlier decision is final and determined all the relevant issues that were capable of determination at the time (R v Smith; Ex parte Mole Engineering Pty Ltd [1981] HCA 25; (1981) 147 CLR…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Abbott Medical Optics, Inc. v Alcon Laboratories, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] APO 78
Decision Date

CaseChat Overview and Summary

Abbott Medical Optics, Inc. opposed the grant of patent application 2004201867 to Alcon Laboratories, Inc. The application related to a process for cleaning and disinfecting contact lenses. The dispute was heard by Dr B. Akhurst, a delegate of the Commissioner of Patents, and determined by written submissions. The central legal issue was whether the applicant’s amendments to the specification and claims overcame the deficiencies identified in the earlier decision.

Alcon had filed amendments to the specification under section 104 of the Patents Act, which were advertised allowed on 31 May 2012. The earlier decision had found that the claims were not novel, lacked an inventive step and were not clear. The court had to determine if the amendments made the claims novel, inventive and clear. The amended claims incorporated part of opposed claim 6 into claim 1, added and deleted text in claims 2 and 7, corrected a typographical error in claim 20 and added two additional claims. The court found that the amended claim 1 was directed to the use of a single solution, unlike Steps 2 and 3 of the Opti-Free® RDS package insert which used two solutions in combination. The pre-treatment step in amended claim 1 was not taught by the prior art documents. Therefore, the court found that the amended claims defined novel and inventive subject matter. The correction of the typographical error in claim 20 rendered it clear.

The court concluded that Alcon’s amendments overcame the deficiencies in the opposed claims. Costs were awarded to the applicant as the opponent was unsuccessful.

Background

Background to the litigation

The case revolves around a patent application for a "Process for cleaning and disinfecting contact lenses" submitted by Alcon Laboratories, Inc. The patent application, numbered 2004201867, was opposed by Abbott Medical Optics, Inc. The opposition was initially upheld by a decision dated 26 September 2011. Following this decision, Alcon Laboratories, Inc. filed amendments to the specification under section 104, which were subsequently advertised as allowed on 31 May 2012. Both parties then filed written submissions for the final determination of the opposition. Alcon's submissions were filed on 12 June 2012, while Abbott's submissions, which were made on 29 June 2012, relied in part on comments on the proposed amendments filed on 14 December 2011. The amendments incorporated part of opposed claim 6 into claim 1, added and deleted text in claims 2 and 7 respectively, corrected a typographical error in claim 20, and added two additional claims. Consequential amendments were made to the dependent claims.

The matter initially came before the Australian Patent Office as an opposition to the patent application 2004201867 by Abbott Medical Optics, Inc. against Alcon Laboratories, Inc. Following a hearing on 26 September 2011, the opposition was upheld, as reported in Abbott Medical Optics, Inc. v Alcon Laboratories, Inc. [2011] APO 79. Subsequently, Alcon Laboratories, Inc. filed amendments to the specification, which were advertised as allowed on 31 May 2012. Both parties submitted written arguments for the final determination of the opposition. Alcon filed its submissions on 12 June 2012, and Abbott submitted its arguments on 29 June 2012, referencing comments on the proposed amendments from 14 December 2011.

Decision

Reasons for decision

Issues
1. Whether Alcon's amendments of 21 November 2011 overcome the deficiencies identified in the earlier decision.
2. Whether the amendments to the claims ensure the patent is novel, involves an inventive step, and is clear.

Held
1. The court found that Alcon's amendments of 21 November 2011 overcome all the deficiencies identified in the earlier decision. The opposition was dismissed, and the application was directed to proceed to sealing.
2. The court awarded costs according to Schedule 8 against Abbott Medical Optics, Inc.

Ratio Decidendi

Legal Principle Established

In considering the amendments to the patent claims, the court examined whether they overcame the deficiencies identified in the earlier decision, which included issues of novelty, inventive step, and clarity. The court found that the amendments made to the claims, particularly to claim 1, were sufficient to overcome the earlier deficiencies. Specifically, the amendments incorporated part of opposed claim 6 into claim 1, altered claims 2 and 7, corrected a typographical error in claim 20, and introduced additional claims. The court concluded that claim 1, as amended, was novel and involved an inventive step over the prior art, including the Opti-Free® RDS package insert and the prior patents cited by Abbott. The amendments ensured that claim 1 was directed to the use of a single solution, thereby distinguishing it from the prior art which involved the use of multiple solutions. Additionally, the correction of a typographical error in claim 20 rendered it clear. These findings led the court to direct that the patent application proceed to sealing, dismissing the opposition. The court also awarded costs against Abbott Medical Optics, Inc., as they were the unsuccessful party in the opposition.